Journals / Nöropsikiyatri Arşivi / 2019 / Cilt: 56 - Sayı: 3

Translation and Validation of the Turkish Version of Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)

Multiple Skleroz Tedaviye Uyum Anketi (MS-TAQ)’nin Türkçe Versiyonu ve Geçerliği

Pages
191–194
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According toexpert’s suggestion modifications was made and content validity indexwas calculated with Davis technic between 1.0–1.4.Conclusion: As a result, “MS-TAQ” has been found a sufficiently valid andreliable tool in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Poor adherence is widely observed in MS as in otherchronic diseases; therefore, improving adherence should be a significanttreatment objective.
📊
Key Findings & Data:The aim of this study is to investigatevalidity and Turkish equivalence of The Multiple Sclerosis TreatmentAdherence Questionnaire (MS-TAQ) that developed by Paul Wicks andMichael Massagli in 2009.Methods: The sample of the methodological study comprised 198 MSpatients who stayed in University Faculty of Medicine, Departmentof Neurology, MS clinic between July 2016 and February 2017.
💡
Conclusion & Impact:According toexpert’s suggestion modifications was made and content validity indexwas calculated with Davis technic between 1.0–1.4.Conclusion: As a result, “MS-TAQ” has been found a sufficiently valid andreliable tool in Turkey.
🔬Design:Survey & Empirical Study
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Poor adherence is widely observed in MS as in otherchronic diseases; therefore, improving adherence should be a significanttreatment objective. Therefore, it is important to determine the causes ofnonadherence and to make improvement plans by establishing a specialmeasurement tool for MS patients. The aim of this study is to investigatevalidity and Turkish equivalence of The Multiple Sclerosis TreatmentAdherence Questionnaire (MS-TAQ) that developed by Paul Wicks andMichael Massagli in 2009.Methods: The sample of the methodological study comprised 198 MSpatients who stayed in University Faculty of Medicine, Departmentof Neurology, MS clinic between July 2016 and February 2017. In theresearch, “Data Collection Form” and “MS-TAQ” was used. To conductthis study, permission was obtained from the university ethics committeeand the hospital administration. All participants in the study wereinformed of the study’s purpose and their role.Results: Translation procedure (forward and backward) and pre-testwere performed for translation equivalence and linguistic adaptation.MS-TAQ’s Cronbach alfa coefficient 0.83 were calculated. According toexpert’s suggestion modifications was made and content validity indexwas calculated with Davis technic between 1.0–1.4.Conclusion: As a result, “MS-TAQ” has been found a sufficiently valid andreliable tool in Turkey.

Özet

Amaç: Diğer kronik hastalıkların yanında MS’de de zayıf uyum yaygındır ve uyumun iyileştirilmesi önemli bir tedavi hedefi olarak tanımlanmalıdır. Bu nedenle MS hastalarına özel bir uyum ölçme aracının oluşturularak uyumsuzluk nedenlerinin saptanması ve buna yönelik iyileştirme planlarının yapılması önemlidir. Bu araştırmanın amacı, Paul Wicks ve Michael Massagli tarafından 2009 yılında geliştirilen Multiple Skleroz Tedaviye Uyum Anketi (MS-TAQ)’in Türkçe eşdeğerliliğini sağlamak ve geçerliğini belirlemektir. Yöntem: Bu metodolojik araştırmanın çalışma grubunu, Temmuz 2016 – Şubat 2017 tarihleri arasında bir Üniversite Hastanesi’nin Nöroloji birimindeki MS polikliniğine başvuran, araştırmayı kabul eden ve araştırma sınırlarına uyan 198 MS hastası oluşturmuştur. Araştırmada veri toplama araçları olarak; Birey Tanıtım Formu ve Multiple Skleroz Tedaviye Uyum Anketi kullanılmıştır. Araştırmanın yürütülebilmesi için etik kuruldan ve kurumdan yazılı izin, hastalardan da yazılı onamları alınmıştır. Bulgular: Anketin dil eşdeğerliğinin sağlanması için Türkçe’ye çevirisi, geri çevirisi ve ön uygulaması yapılmıştır. MS-TAQ anketinin cronbach alfa katsayısı 0.83 olarak bulunmuştur. Anketin kapsam geçerliğini sınamak için uzmanlardan görüş alınarak gerekli değişiklikler yapılmış, Davis kapsam geçerlik indeksi 1.0 ile 1.4 arasında bulunmuştur. Sonuç: “MS-TAQ” Türk toplumu için yeterli güvenirlik ve geçerliğe sahip bir ölçme aracı olarak bulunmuştur.

🔖

Cite This Article

ERBAY, Ö., YEŞİLBALKAN, Ö. U., YÜCEYAR, A. N. (2022). Translation and Validation of the Turkish Version of Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). Nöropsikiyatri Arşivi, Cilt: 56 - Sayı: 3, 191–194. https://ajindex.com/articles/584664

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr Neurol Neurosci Rep 2010
  2. 381–88. [CrossRef] 2. Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm 2016
  3. 1394–1401. [CrossRef] 3. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in middle east and north africa: a systematic review and meta-analysis. Neuroepidemiology 2015
  4. 232–244. [CrossRef] 4. Ozura A, Kocav L, Sega S. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clin Neurol Neurosurg 2013
  5. S6–S11. [CrossRef] 5. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010
  6. 1–9. [CrossRef] 6. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2003
  7. [CrossRef] 7. Misdrahi D, Liorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutica considerations and research implications. Encephale 2002
  8. 266–72. 8. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005
  9. 313–56. [CrossRef] 9. Wicks P, Massagli M, Kulkarni A, Dastani H. Use of an online community to develop patient-reported outcome instruments: the multiple sclerosis treatment adherence questionnaire (MS-TAQ). J Med Internet Res 2011
  10. [CrossRef] 10. Erkut S, Alarcon O, Garcia Coll C, TropLR, Vazguez Garcia HA. The dual-focus approach to creating bilingual measures. J Cross Cult Psychol 1999
  11. 206– 218. [CrossRef] 11. Polit DF, Beck CT, editors. Nursing Research: Principles and Methods, 7th ed. USA-Philadelphia PA: Lippincott Williams & Wilkins
  12. Gözüm S, Aksayan S. Kültürlerarası Ölçek Uyarlaması için Rehber II. Psikometrik Özellikler ve Kültürlerarası Karşılaştırma. Hemşirelik Araştırma Dergisi 2003
  13. 3–14. 13. Polit DF, Beck CD. The Content Validity Index: Are you sure you know what’s being reported? Critique and recommendations. Res Nurs Health 2006
  14. 489–97. [CrossRef] 14. Zamanzadeh V, Ghahramanian A, Rassouli M, Abbaszadeh A, Alavi-Majd H, Nikanfar AR. Design and implementation content validity study: development of an ınstrument for measuring patient-centered communication. J Caring Sci 2015
  15. 165–78. [CrossRef] 15. Burns N, Grove SK, editors. The practice of nursing research: conduct, critique and utilisa